Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2021-03-16 Director's Dealing
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document explicitly contains the header "Directors’ Dealings" and details transactions made by a person discharging managerial responsibilities (Oliver R. Baumann, Member of the managing body). Section 4 details the nature of the transaction ('Acquisition'), the financial instrument (Share), price, volume, and date. This content directly corresponds to the definition of Director's Dealing.
2021-03-16 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: Xlife Sciences AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. The content details the transaction (Acquisition), the person involved (Mark Müller, Member of the administrative or supervisory body), the financial instrument, price, volume, and date. This perfectly matches the definition for Director's Dealing (DIRS). The document length is short (2186 chars), but the content is the primary disclosure itself, not an announcement *about* a disclosure, thus DIRS is the correct classification over RPA or RNS.
2021-03-05 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an executive (Oliver R. Baumann), their position ('Member of the managing body'), the nature of the transaction ('Acquisition'), the price, volume, and date of the transaction involving shares of Xlife Sciences AG. This content directly matches the definition for Director's Dealing.
2021-03-05 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the transaction (Acquisition), the person involved (Oliver R. Baumann, Member of the managing body), the instrument (Share), and the date/price. This content directly matches the definition for Director's Dealing.
2021-03-05 English
Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies
Regulatory Filings Classification · 1% confidence The document is a news release dated March 5, 2021, announcing a joint venture between Xlife Sciences AG and anfass Life Technologies AG regarding antibody development using 3D cell technology. It contains keywords like 'DGAP-News', 'Corporate News', and details about a business transaction (joint venture/merger). This type of announcement, detailing a significant business development that is not a standard periodic financial report (like 10-K or IR), typically falls under general corporate news or M&A activity. Since the core event is the formation of a joint venture, the 'Merger' keyword mentioned in the metadata suggests M&A Activity (TAR). However, the document is structured as a general news release distributed via DGAP, which often serves as a catch-all for material non-public information not covered by other specific forms. Given the nature of the announcement (a strategic business partnership/JV), it is most accurately classified as M&A Activity (TAR). If TAR was not available, RNS would be a strong secondary choice, but TAR fits the 'Merger' context better.
2021-03-05 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the transaction (Acquisition) by a specific individual (Oliver Baumann), who is a 'Member of the managing body' of Xlife Sciences AG, including the date, price, and volume of shares traded. This perfectly matches the definition for Director's Dealing (DIRS).
2021-02-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.